To evaluate the effect of MYO1C‐rich EVs mediated by RAB31 on glioma progression, U87MG cells and GSC2 were treated with EVs from control GhECs (siNC), RAB31 knockdown GhEC (siRAB31), or NhECs. The gene discussed is RAB31; the disease is central nervous system cancer.